NCT01098513 - GSK1349572 Relative Bioavailability Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

June 30, 2010

Study Completion Date

July 31, 2010

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

GSK1349572 formulation AP

GSK1349572 50 mg single dose fasted.

DRUG

GSK1349572 formulation AW

GSK1349572 formulation AW 50 mg single dose in Part A and 75 to 200 mg fasted or with moderate or high fat meal in Part B.

DRUG

GSK1349572 formulation AX

GSK1349572 formulation AX 50 mg in Part A and 75-200 mg fasted or with a moderate or high fat meal in Part B

Trial Locations (1)

GSK Investigational Site, Austin